nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—L-Phenylalanine—Melphalan—ovarian cancer	0.86	1	CrCrCtD
Phenylpropanolamine—Ataxia—Altretamine—ovarian cancer	0.00583	0.0595	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Chlorambucil—ovarian cancer	0.00323	0.033	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—IL2—ovarian cancer	0.00317	1	CrCbGaD
Phenylpropanolamine—Hepatocellular injury—Melphalan—ovarian cancer	0.00265	0.027	CcSEcCtD
Phenylpropanolamine—Ataxia—Chlorambucil—ovarian cancer	0.00207	0.0211	CcSEcCtD
Phenylpropanolamine—Dizziness—Altretamine—ovarian cancer	0.00201	0.0206	CcSEcCtD
Phenylpropanolamine—Vomiting—Altretamine—ovarian cancer	0.00194	0.0198	CcSEcCtD
Phenylpropanolamine—Nausea—Altretamine—ovarian cancer	0.00181	0.0185	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Paclitaxel—ovarian cancer	0.00165	0.0169	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Paclitaxel—ovarian cancer	0.00155	0.0159	CcSEcCtD
Phenylpropanolamine—Hallucination—Chlorambucil—ovarian cancer	0.00152	0.0155	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Docetaxel—ovarian cancer	0.00132	0.0135	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Docetaxel—ovarian cancer	0.00132	0.0135	CcSEcCtD
Phenylpropanolamine—Tremor—Chlorambucil—ovarian cancer	0.00124	0.0127	CcSEcCtD
Phenylpropanolamine—Flushing—Melphalan—ovarian cancer	0.00123	0.0126	CcSEcCtD
Phenylpropanolamine—Agitation—Chlorambucil—ovarian cancer	0.00122	0.0124	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Melphalan—ovarian cancer	0.00119	0.0121	CcSEcCtD
Phenylpropanolamine—Confusional state—Chlorambucil—ovarian cancer	0.00109	0.0111	CcSEcCtD
Phenylpropanolamine—Flushing—Vinorelbine—ovarian cancer	0.00108	0.011	CcSEcCtD
Phenylpropanolamine—Ataxia—Paclitaxel—ovarian cancer	0.00106	0.0108	CcSEcCtD
Phenylpropanolamine—Liver injury—Epirubicin—ovarian cancer	0.00106	0.0108	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Vinorelbine—ovarian cancer	0.00104	0.0106	CcSEcCtD
Phenylpropanolamine—Liver injury—Doxorubicin—ovarian cancer	0.000977	0.00998	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Epirubicin—ovarian cancer	0.000946	0.00965	CcSEcCtD
Phenylpropanolamine—Tachycardia—Melphalan—ovarian cancer	0.000921	0.0094	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Epirubicin—ovarian cancer	0.000905	0.00924	CcSEcCtD
Phenylpropanolamine—Ataxia—Docetaxel—ovarian cancer	0.000899	0.00918	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Chlorambucil—ovarian cancer	0.000892	0.00911	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Epirubicin—ovarian cancer	0.000889	0.00907	CcSEcCtD
Phenylpropanolamine—Hypotension—Melphalan—ovarian cancer	0.000882	0.009	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—ovarian cancer	0.000875	0.00893	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Topotecan—ovarian cancer	0.000859	0.00877	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Melphalan—ovarian cancer	0.000841	0.00859	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—ovarian cancer	0.000837	0.00855	CcSEcCtD
Phenylpropanolamine—Constipation—Topotecan—ovarian cancer	0.000824	0.00841	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—ovarian cancer	0.000822	0.00839	CcSEcCtD
Phenylpropanolamine—Tachycardia—Vinorelbine—ovarian cancer	0.000805	0.00821	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000798	0.00814	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Topotecan—ovarian cancer	0.000794	0.00811	CcSEcCtD
Phenylpropanolamine—Hypotension—Vinorelbine—ovarian cancer	0.00077	0.00787	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Vinorelbine—ovarian cancer	0.000735	0.0075	CcSEcCtD
Phenylpropanolamine—Flushing—Paclitaxel—ovarian cancer	0.000724	0.0074	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Topotecan—ovarian cancer	0.00071	0.00725	CcSEcCtD
Phenylpropanolamine—Constipation—Vinorelbine—ovarian cancer	0.000705	0.0072	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Paclitaxel—ovarian cancer	0.000697	0.00712	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Melphalan—ovarian cancer	0.000695	0.0071	CcSEcCtD
Phenylpropanolamine—Vomiting—Chlorambucil—ovarian cancer	0.000688	0.00703	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000679	0.00694	CcSEcCtD
Phenylpropanolamine—Tension—Paclitaxel—ovarian cancer	0.000667	0.00681	CcSEcCtD
Phenylpropanolamine—Nervousness—Paclitaxel—ovarian cancer	0.00066	0.00674	CcSEcCtD
Phenylpropanolamine—Nausea—Chlorambucil—ovarian cancer	0.000643	0.00657	CcSEcCtD
Phenylpropanolamine—Vision blurred—Paclitaxel—ovarian cancer	0.00064	0.00654	CcSEcCtD
Phenylpropanolamine—Dizziness—Topotecan—ovarian cancer	0.000637	0.00651	CcSEcCtD
Phenylpropanolamine—Tremor—Paclitaxel—ovarian cancer	0.000637	0.0065	CcSEcCtD
Phenylpropanolamine—Agitation—Paclitaxel—ovarian cancer	0.000624	0.00637	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—ovarian cancer	0.000614	0.00627	CcSEcCtD
Phenylpropanolamine—Vomiting—Topotecan—ovarian cancer	0.000613	0.00626	CcSEcCtD
Phenylpropanolamine—Rash—Topotecan—ovarian cancer	0.000608	0.0062	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000607	0.0062	CcSEcCtD
Phenylpropanolamine—Dermatitis—Topotecan—ovarian cancer	0.000607	0.0062	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—ovarian cancer	0.000607	0.00619	CcSEcCtD
Phenylpropanolamine—Vomiting—Melphalan—ovarian cancer	0.0006	0.00613	CcSEcCtD
Phenylpropanolamine—Rash—Melphalan—ovarian cancer	0.000595	0.00607	CcSEcCtD
Phenylpropanolamine—Dermatitis—Melphalan—ovarian cancer	0.000594	0.00607	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Docetaxel—ovarian cancer	0.000591	0.00603	CcSEcCtD
Phenylpropanolamine—Anxiety—Paclitaxel—ovarian cancer	0.000577	0.00589	CcSEcCtD
Phenylpropanolamine—Nausea—Topotecan—ovarian cancer	0.000573	0.00584	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—ovarian cancer	0.000561	0.00573	CcSEcCtD
Phenylpropanolamine—Nausea—Melphalan—ovarian cancer	0.000561	0.00572	CcSEcCtD
Phenylpropanolamine—Confusional state—Paclitaxel—ovarian cancer	0.000559	0.00571	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinorelbine—ovarian cancer	0.000545	0.00557	CcSEcCtD
Phenylpropanolamine—Tachycardia—Paclitaxel—ovarian cancer	0.000541	0.00553	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinorelbine—ovarian cancer	0.000524	0.00535	CcSEcCtD
Phenylpropanolamine—Rash—Vinorelbine—ovarian cancer	0.00052	0.00531	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vinorelbine—ovarian cancer	0.000519	0.0053	CcSEcCtD
Phenylpropanolamine—Hypotension—Paclitaxel—ovarian cancer	0.000518	0.00529	CcSEcCtD
Phenylpropanolamine—Insomnia—Paclitaxel—ovarian cancer	0.000502	0.00512	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—ovarian cancer	0.000497	0.00507	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Paclitaxel—ovarian cancer	0.000494	0.00505	CcSEcCtD
Phenylpropanolamine—Somnolence—Paclitaxel—ovarian cancer	0.000493	0.00503	CcSEcCtD
Phenylpropanolamine—Nausea—Vinorelbine—ovarian cancer	0.00049	0.005	CcSEcCtD
Phenylpropanolamine—Constipation—Paclitaxel—ovarian cancer	0.000474	0.00484	CcSEcCtD
Phenylpropanolamine—Confusional state—Docetaxel—ovarian cancer	0.000474	0.00484	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—ovarian cancer	0.00046	0.0047	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—ovarian cancer	0.000459	0.00468	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000457	0.00467	CcSEcCtD
Phenylpropanolamine—Hypotension—Docetaxel—ovarian cancer	0.000439	0.00448	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—ovarian cancer	0.000425	0.00434	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—ovarian cancer	0.000419	0.00428	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—ovarian cancer	0.000418	0.00427	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—ovarian cancer	0.000414	0.00423	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000409	0.00417	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—ovarian cancer	0.000402	0.0041	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—ovarian cancer	0.000399	0.00407	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—ovarian cancer	0.000387	0.00395	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—ovarian cancer	0.000383	0.00391	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—ovarian cancer	0.000381	0.00389	CcSEcCtD
Phenylpropanolamine—Nervousness—Epirubicin—ovarian cancer	0.000377	0.00385	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—ovarian cancer	0.000369	0.00377	CcSEcCtD
Phenylpropanolamine—Dizziness—Paclitaxel—ovarian cancer	0.000367	0.00374	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—ovarian cancer	0.000366	0.00374	CcSEcCtD
Phenylpropanolamine—Agitation—Epirubicin—ovarian cancer	0.000357	0.00364	CcSEcCtD
Phenylpropanolamine—Tension—Doxorubicin—ovarian cancer	0.000353	0.0036	CcSEcCtD
Phenylpropanolamine—Vomiting—Paclitaxel—ovarian cancer	0.000353	0.0036	CcSEcCtD
Phenylpropanolamine—Rash—Paclitaxel—ovarian cancer	0.00035	0.00357	CcSEcCtD
Phenylpropanolamine—Dermatitis—Paclitaxel—ovarian cancer	0.000349	0.00357	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—ovarian cancer	0.000349	0.00356	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000346	0.00354	CcSEcCtD
Phenylpropanolamine—MAOA—myometrium—ovarian cancer	0.000346	0.0561	CbGeAlD
Phenylpropanolamine—Vision blurred—Doxorubicin—ovarian cancer	0.000339	0.00346	CcSEcCtD
Phenylpropanolamine—MAOA—embryo—ovarian cancer	0.000332	0.0539	CbGeAlD
Phenylpropanolamine—Agitation—Doxorubicin—ovarian cancer	0.00033	0.00337	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—ovarian cancer	0.00033	0.00336	CcSEcCtD
Phenylpropanolamine—Nausea—Paclitaxel—ovarian cancer	0.000329	0.00336	CcSEcCtD
Phenylpropanolamine—Confusional state—Epirubicin—ovarian cancer	0.00032	0.00326	CcSEcCtD
Phenylpropanolamine—Dizziness—Docetaxel—ovarian cancer	0.000311	0.00317	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—ovarian cancer	0.000309	0.00316	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—ovarian cancer	0.000305	0.00311	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—ovarian cancer	0.000299	0.00305	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—ovarian cancer	0.000296	0.00303	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—ovarian cancer	0.000296	0.00302	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—ovarian cancer	0.000296	0.00302	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—ovarian cancer	0.000296	0.00302	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—ovarian cancer	0.000287	0.00293	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—ovarian cancer	0.000286	0.00292	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Epirubicin—ovarian cancer	0.000283	0.00289	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—ovarian cancer	0.000282	0.00288	CcSEcCtD
Phenylpropanolamine—Nausea—Docetaxel—ovarian cancer	0.000279	0.00285	CcSEcCtD
Phenylpropanolamine—SLC6A2—decidua—ovarian cancer	0.000278	0.0451	CbGeAlD
Phenylpropanolamine—Hypotension—Doxorubicin—ovarian cancer	0.000274	0.0028	CcSEcCtD
Phenylpropanolamine—ADRA1A—epithelium—ovarian cancer	0.000274	0.0444	CbGeAlD
Phenylpropanolamine—Constipation—Epirubicin—ovarian cancer	0.000271	0.00277	CcSEcCtD
Phenylpropanolamine—MAOA—uterine cervix—ovarian cancer	0.000269	0.0436	CbGeAlD
Phenylpropanolamine—Insomnia—Doxorubicin—ovarian cancer	0.000265	0.00271	CcSEcCtD
Phenylpropanolamine—ADRA2A—myometrium—ovarian cancer	0.000265	0.043	CbGeAlD
Phenylpropanolamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000262	0.00267	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—ovarian cancer	0.000261	0.00267	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—ovarian cancer	0.000261	0.00266	CcSEcCtD
Phenylpropanolamine—ADRB1—female reproductive system—ovarian cancer	0.000257	0.0417	CbGeAlD
Phenylpropanolamine—MAOA—decidua—ovarian cancer	0.000256	0.0416	CbGeAlD
Phenylpropanolamine—Constipation—Doxorubicin—ovarian cancer	0.000251	0.00256	CcSEcCtD
Phenylpropanolamine—SLC6A2—gonad—ovarian cancer	0.000245	0.0397	CbGeAlD
Phenylpropanolamine—MAOA—endometrium—ovarian cancer	0.000243	0.0395	CbGeAlD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000242	0.00247	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000234	0.00238	CcSEcCtD
Phenylpropanolamine—MAOA—uterus—ovarian cancer	0.000224	0.0364	CbGeAlD
Phenylpropanolamine—SLC6A3—testis—ovarian cancer	0.000219	0.0355	CbGeAlD
Phenylpropanolamine—SLC6A2—female reproductive system—ovarian cancer	0.000219	0.0355	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000216	0.00221	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—ovarian cancer	0.00021	0.00214	CcSEcCtD
Phenylpropanolamine—ADRA2A—uterine cervix—ovarian cancer	0.000206	0.0335	CbGeAlD
Phenylpropanolamine—Vomiting—Epirubicin—ovarian cancer	0.000202	0.00206	CcSEcCtD
Phenylpropanolamine—MAOA—female reproductive system—ovarian cancer	0.000201	0.0327	CbGeAlD
Phenylpropanolamine—Rash—Epirubicin—ovarian cancer	0.0002	0.00204	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—ovarian cancer	0.0002	0.00204	CcSEcCtD
Phenylpropanolamine—ADRA2A—decidua—ovarian cancer	0.000197	0.0319	CbGeAlD
Phenylpropanolamine—Dizziness—Doxorubicin—ovarian cancer	0.000194	0.00198	CcSEcCtD
Phenylpropanolamine—Nausea—Epirubicin—ovarian cancer	0.000188	0.00192	CcSEcCtD
Phenylpropanolamine—ADRA2A—endometrium—ovarian cancer	0.000187	0.0303	CbGeAlD
Phenylpropanolamine—Vomiting—Doxorubicin—ovarian cancer	0.000187	0.0019	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—ovarian cancer	0.000185	0.00189	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—ovarian cancer	0.000185	0.00189	CcSEcCtD
Phenylpropanolamine—MAOA—female gonad—ovarian cancer	0.000183	0.0297	CbGeAlD
Phenylpropanolamine—MAOA—vagina—ovarian cancer	0.000182	0.0296	CbGeAlD
Phenylpropanolamine—SLC6A2—testis—ovarian cancer	0.000176	0.0286	CbGeAlD
Phenylpropanolamine—Nausea—Doxorubicin—ovarian cancer	0.000174	0.00178	CcSEcCtD
Phenylpropanolamine—ADRA2A—gonad—ovarian cancer	0.000173	0.0281	CbGeAlD
Phenylpropanolamine—ADRA2A—uterus—ovarian cancer	0.000172	0.0279	CbGeAlD
Phenylpropanolamine—MAOA—testis—ovarian cancer	0.000163	0.0264	CbGeAlD
Phenylpropanolamine—ADRA2A—female reproductive system—ovarian cancer	0.000155	0.0251	CbGeAlD
Phenylpropanolamine—ADRA2A—female gonad—ovarian cancer	0.000141	0.0228	CbGeAlD
Phenylpropanolamine—ADRA2A—vagina—ovarian cancer	0.00014	0.0227	CbGeAlD
Phenylpropanolamine—SLC6A2—lymph node—ovarian cancer	0.000128	0.0207	CbGeAlD
Phenylpropanolamine—ADRA2A—testis—ovarian cancer	0.000125	0.0202	CbGeAlD
Phenylpropanolamine—MAOA—lymph node—ovarian cancer	0.000118	0.0191	CbGeAlD
Phenylpropanolamine—ADRA2A—lymph node—ovarian cancer	9.04e-05	0.0147	CbGeAlD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CD—ovarian cancer	1.09e-05	0.000336	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.08e-05	0.000335	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CG—ovarian cancer	1.08e-05	0.000334	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APC—ovarian cancer	1.08e-05	0.000334	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NRAS—ovarian cancer	1.08e-05	0.000334	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCL8—ovarian cancer	1.08e-05	0.000334	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CAV1—ovarian cancer	1.07e-05	0.00033	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CAV1—ovarian cancer	1.04e-05	0.000323	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CB—ovarian cancer	1.04e-05	0.000323	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK3—ovarian cancer	1.03e-05	0.00032	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—IL2—ovarian cancer	1.03e-05	0.000319	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ESR1—ovarian cancer	1.03e-05	0.000318	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CB—ovarian cancer	1.02e-05	0.000315	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6ST—ovarian cancer	1.01e-05	0.000313	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PIK3CA—ovarian cancer	1.01e-05	0.000311	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—ovarian cancer	1e-05	0.000311	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCL8—ovarian cancer	1e-05	0.00031	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CB—ovarian cancer	1e-05	0.00031	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6ST—ovarian cancer	9.89e-06	0.000306	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—MAPK1—ovarian cancer	9.84e-06	0.000305	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EGFR—ovarian cancer	9.84e-06	0.000305	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCL8—ovarian cancer	9.79e-06	0.000303	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—ovarian cancer	9.73e-06	0.000301	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APC—ovarian cancer	9.71e-06	0.0003	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CG—ovarian cancer	9.71e-06	0.0003	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NRAS—ovarian cancer	9.71e-06	0.0003	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CAV1—ovarian cancer	9.58e-06	0.000297	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—IL2—ovarian cancer	9.58e-06	0.000296	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.51e-06	0.000294	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CG—ovarian cancer	9.5e-06	0.000294	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APC—ovarian cancer	9.5e-06	0.000294	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NRAS—ovarian cancer	9.5e-06	0.000294	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CD—ovarian cancer	9.5e-06	0.000294	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CB—ovarian cancer	9.47e-06	0.000293	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—PIK3CA—ovarian cancer	9.4e-06	0.000291	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL2—ovarian cancer	9.36e-06	0.00029	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TERT—ovarian cancer	9.33e-06	0.000289	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HRAS—ovarian cancer	9.31e-06	0.000288	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK3—ovarian cancer	9.3e-06	0.000288	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KRAS—ovarian cancer	9.3e-06	0.000288	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCL8—ovarian cancer	9.1e-06	0.000282	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK3—ovarian cancer	9.1e-06	0.000281	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—FASN—ovarian cancer	8.91e-06	0.000276	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—MAPK1—ovarian cancer	8.85e-06	0.000274	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EGFR—ovarian cancer	8.85e-06	0.000274	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	8.77e-06	0.000271	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CG—ovarian cancer	8.73e-06	0.00027	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL2—ovarian cancer	8.7e-06	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TERT—ovarian cancer	8.66e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—MAPK1—ovarian cancer	8.66e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—ovarian cancer	8.65e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTEN—ovarian cancer	8.65e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CAV1—ovarian cancer	8.63e-06	0.000267	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PIK3CA—ovarian cancer	8.54e-06	0.000264	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CD—ovarian cancer	8.54e-06	0.000264	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	8.47e-06	0.000262	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—PIK3CA—ovarian cancer	8.46e-06	0.000262	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB2—ovarian cancer	8.39e-06	0.00026	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—ovarian cancer	8.36e-06	0.000259	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CD—ovarian cancer	8.35e-06	0.000258	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—ovarian cancer	8.31e-06	0.000257	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.29e-06	0.000257	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—ovarian cancer	8.28e-06	0.000256	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CB—ovarian cancer	8.28e-06	0.000256	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—PIK3CA—ovarian cancer	8.27e-06	0.000256	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—ovarian cancer	8.22e-06	0.000254	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6ST—ovarian cancer	8.18e-06	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—ovarian cancer	8.18e-06	0.000253	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	8.12e-06	0.000251	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	8.01e-06	0.000248	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—ovarian cancer	7.95e-06	0.000246	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—ovarian cancer	7.9e-06	0.000245	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	7.86e-06	0.000243	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—ovarian cancer	7.86e-06	0.000243	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	7.86e-06	0.000243	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1B—ovarian cancer	7.77e-06	0.00024	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	7.72e-06	0.000239	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—ovarian cancer	7.68e-06	0.000238	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—ovarian cancer	7.68e-06	0.000238	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—ovarian cancer	7.67e-06	0.000237	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—ovarian cancer	7.61e-06	0.000236	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—ovarian cancer	7.6e-06	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	7.6e-06	0.000235	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—ovarian cancer	7.56e-06	0.000234	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—ovarian cancer	7.54e-06	0.000233	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	7.52e-06	0.000233	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—ovarian cancer	7.51e-06	0.000232	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—ovarian cancer	7.44e-06	0.00023	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—ovarian cancer	7.44e-06	0.00023	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—ovarian cancer	7.41e-06	0.000229	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—ovarian cancer	7.38e-06	0.000228	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—ovarian cancer	7.34e-06	0.000227	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	7.3e-06	0.000226	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—ovarian cancer	7.3e-06	0.000226	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	7.3e-06	0.000226	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—ovarian cancer	7.28e-06	0.000225	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—ovarian cancer	7.28e-06	0.000225	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	7.2e-06	0.000223	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—ovarian cancer	7.19e-06	0.000223	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.17e-06	0.000222	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	7.16e-06	0.000222	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	7.16e-06	0.000221	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—ovarian cancer	7.15e-06	0.000221	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—ovarian cancer	7.15e-06	0.000221	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—ovarian cancer	7.1e-06	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—ovarian cancer	6.99e-06	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	6.99e-06	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1B—ovarian cancer	6.98e-06	0.000216	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—ovarian cancer	6.98e-06	0.000216	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—ovarian cancer	6.95e-06	0.000215	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—ovarian cancer	6.91e-06	0.000214	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	6.91e-06	0.000214	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—ovarian cancer	6.84e-06	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.84e-06	0.000212	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—ovarian cancer	6.83e-06	0.000211	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1B—ovarian cancer	6.83e-06	0.000211	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—ovarian cancer	6.8e-06	0.00021	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	6.76e-06	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	6.76e-06	0.000209	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—ovarian cancer	6.69e-06	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	6.69e-06	0.000207	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—ovarian cancer	6.69e-06	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—ovarian cancer	6.68e-06	0.000207	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—ovarian cancer	6.66e-06	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	6.65e-06	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—ovarian cancer	6.65e-06	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	6.65e-06	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	6.6e-06	0.000204	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TYMS—ovarian cancer	6.57e-06	0.000203	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—ovarian cancer	6.52e-06	0.000202	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—ovarian cancer	6.47e-06	0.0002	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—ovarian cancer	6.46e-06	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	6.45e-06	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—ovarian cancer	6.43e-06	0.000199	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	6.42e-06	0.000199	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—ovarian cancer	6.4e-06	0.000198	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—ovarian cancer	6.38e-06	0.000197	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.36e-06	0.000197	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—ovarian cancer	6.33e-06	0.000196	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—ovarian cancer	6.29e-06	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	6.28e-06	0.000194	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	6.27e-06	0.000194	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	6.21e-06	0.000192	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	6.14e-06	0.00019	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—ovarian cancer	6.11e-06	0.000189	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—ovarian cancer	6.1e-06	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	6.1e-06	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	6.02e-06	0.000186	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	6.02e-06	0.000186	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—ovarian cancer	5.94e-06	0.000184	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK1—ovarian cancer	5.81e-06	0.00018	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—ovarian cancer	5.81e-06	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	5.81e-06	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	5.79e-06	0.000179	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—ovarian cancer	5.78e-06	0.000179	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.77e-06	0.000179	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—ovarian cancer	5.75e-06	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	5.75e-06	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—ovarian cancer	5.74e-06	0.000177	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	5.68e-06	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	5.67e-06	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	5.65e-06	0.000175	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—ovarian cancer	5.62e-06	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—ovarian cancer	5.61e-06	0.000174	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.59e-06	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.59e-06	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	5.59e-06	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	5.54e-06	0.000171	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	5.53e-06	0.000171	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	5.5e-06	0.00017	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	5.49e-06	0.00017	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—ovarian cancer	5.49e-06	0.00017	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	5.39e-06	0.000167	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	5.38e-06	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	5.37e-06	0.000166	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—ovarian cancer	5.34e-06	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	5.34e-06	0.000165	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	5.34e-06	0.000165	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—ovarian cancer	5.29e-06	0.000164	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	5.25e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	5.23e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	5.23e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—ovarian cancer	5.23e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	5.23e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	5.2e-06	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	5.19e-06	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	5.14e-06	0.000159	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	5.14e-06	0.000159	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	5.11e-06	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—ovarian cancer	5.11e-06	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	5.11e-06	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	5.08e-06	0.000157	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.05e-06	0.000156	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	5.05e-06	0.000156	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	5.01e-06	0.000155	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—ovarian cancer	4.99e-06	0.000154	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.96e-06	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	4.94e-06	0.000153	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—ovarian cancer	4.88e-06	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.86e-06	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.83e-06	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—ovarian cancer	4.83e-06	0.000149	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	4.82e-06	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.72e-06	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	4.7e-06	0.000145	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—ovarian cancer	4.67e-06	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	4.65e-06	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	4.64e-06	0.000144	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	4.54e-06	0.00014	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—ovarian cancer	4.47e-06	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	4.44e-06	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	4.44e-06	0.000137	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—ovarian cancer	4.39e-06	0.000136	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.37e-06	0.000135	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	4.32e-06	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.32e-06	0.000134	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.31e-06	0.000133	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—ovarian cancer	4.29e-06	0.000133	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.24e-06	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	4.23e-06	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	4.23e-06	0.000131	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	4.2e-06	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	4.13e-06	0.000128	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—ovarian cancer	4.12e-06	0.000128	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—ovarian cancer	4.11e-06	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	4.08e-06	0.000126	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.02e-06	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—ovarian cancer	4.02e-06	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	3.99e-06	0.000124	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.93e-06	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—ovarian cancer	3.93e-06	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.93e-06	0.000122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.71e-06	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	3.71e-06	0.000115	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.69e-06	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	3.67e-06	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—ovarian cancer	3.62e-06	0.000112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	3.55e-06	0.00011	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.41e-06	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	3.4e-06	0.000105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—ovarian cancer	3.33e-06	0.000103	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.3e-06	0.000102	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	3.25e-06	0.000101	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—ovarian cancer	3.19e-06	9.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.15e-06	9.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.02e-06	9.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3e-06	9.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.79e-06	8.62e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.25e-06	6.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.84e-06	5.69e-05	CbGpPWpGaD
